Skip to main content

Advertisement

SpringerLink
Log in

Development and validation of prognostic nomograms for patients with metastatic prostate cancer

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objective

This study aimed to develop and validate nomograms to predict overall survival (OS) and cancer-specific survival (CSS) in patients with prostate cancer.

Methods

Clinical data of patients with mPCa between 2010 and 2014 were retrieved retrospectively, and randomized into training (2/3) and validation sets (1/3). Nomograms were built with potential risk factors based on COX regression analysis. Accuracy was validated using the discrimination and calibration curve for the training and validation groups, respectively.

Results

6659 mPCa patients were collected and enrolled, including 4440 in the training set and 2219 in the validation set. Multivariate analysis showed that age, marital status, PSA, biopsy Gleason score, T stage, and bone metastasis were independent risk factors for both OS and CSS. The concordance index (C-index) of OS was 0.735 (95% CI 0.722–0.748) for the internal validation and 0.735 (95% CI 0.717–0.753) for the external validation. For CSS, it was 0.734 (95% CI 0.721–0.747) and 0.742 (95% CI 0.723–0.761), respectively. The nomograms for predicting OS and CSS displayed better discrimination power in both training and validation sets. Moreover, a favorable consistency between the predicted and actual survival probabilities was demonstrated using calibration curves.

Conclusions

The nomograms showed good performances for predicting OS and CSS in patients with prostate cancer. It might be a convenient individualized predictive tool for prognosis in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442

    Article  PubMed  Google Scholar 

  2. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M (2014) Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74(2):210–216. https://doi.org/10.1002/pros.22742

    Article  PubMed  Google Scholar 

  3. Huggins C, Hodges CV (1941) Studies on prostatic cancer I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 168(1):293–297

    Google Scholar 

  4. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A (2018) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73(2):178–211. https://doi.org/10.1016/j.eururo.2017.06.002

    Article  PubMed  Google Scholar 

  5. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, Wiegel T, Mottet N (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642. https://doi.org/10.1016/j.eururo.2016.08.002

    Article  PubMed  Google Scholar 

  6. Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA (2014) No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 120(6):818–823. https://doi.org/10.1002/cncr.28485

    Article  CAS  PubMed  Google Scholar 

  7. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67(2):93–99. https://doi.org/10.3322/caac.21388

    Article  PubMed  Google Scholar 

  8. Liu Y, Xia Q, Xia J, Zhu H, Jiang H, Chen X, Zheng Y, Zhang F, Li S (2018) The impact of marriage on the overall survival of prostate cancer patients: a surveillance, epidemiology, and end results (SEER) analysis. Can Urol Assoc J. https://doi.org/10.5489/cuaj.5413

    Article  PubMed  PubMed Central  Google Scholar 

  9. Guo Y, Mao S, Zhang A, Wang R, Zhang Z, Zhang J, Wang L, Zhang W, Wu Y, Ye L, Yang B, Yao X (2019) Prognostic significance of young age and non-bone metastasis at diagnosis in patients with metastatic prostate cancer: a SEER population-based data analysis. J Cancer 10(3):556–567. https://doi.org/10.7150/jca.29481

    Article  PubMed  PubMed Central  Google Scholar 

  10. Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat SF, Tian Z, Saad F, Montorsi F, Zorn KC, Graefen M, Tilki D, Karakiewicz PI (2019) Rates of positive surgical margins and their effect on cancer-specific mortality at radical prostatectomy for patients with clinically localized prostate cancer. Clin Genitourin Cancer 17(1):e130–e139. https://doi.org/10.1016/j.clgc.2018.09.024

    Article  PubMed  Google Scholar 

  11. Gu X, Gao X, Cui M, Xie M, Ma M, Qin S, Li X, Qi X, Bai Y, Wang D (2018) Survival outcomes of radical prostatectomy and external beam radiotherapy in clinically localized high-risk prostate cancer: a population-based, propensity score matched study. Cancer Manag Res 10:1061–1067. https://doi.org/10.2147/CMAR.S157442

    Article  PubMed  PubMed Central  Google Scholar 

  12. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP (2015) Nomograms in oncology: more than meets the eye. Lancet Oncol 16(4):e173–e180. https://doi.org/10.1016/S1470-2045(14)71116-7

    Article  PubMed  PubMed Central  Google Scholar 

  13. Song W, Lv CG, Miao DL, Zhu ZG, Wu Q, Wang YG, Chen L (2018) Development and validation of a nomogram for predicting survival in patients with gastrointestinal stromal tumours. Eur J Surg Oncol 44(10):1657–1665. https://doi.org/10.1016/j.ejso.2018.07.004

    Article  PubMed  Google Scholar 

  14. Iasonos A, Schrag D, Raj GV, Panageas KS (2008) How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26(8):1364–1370. https://doi.org/10.1200/jco.2007.12.9791

    Article  PubMed  Google Scholar 

  15. Attiyeh MA, Fernandez-Del Castillo C, Al Efishat M, Eaton AA, Gonen M, Batts R, Pergolini I, Rezaee N, Lillemoe KD, Ferrone CR, Mino-Kenudson M, Weiss MJ, Cameron JL, Hruban RH, D’Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Wolfgang CL, Allen PJ (2018) Development and validation of a multi-institutional preoperative nomogram for predicting grade of dysplasia in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: a report from the pancreatic surgery consortium. Ann Surg 267(1):157–163. https://doi.org/10.1097/SLA.0000000000002015

    Article  PubMed  Google Scholar 

  16. Huang Z, Sun B, Wu S, Meng X, Cong Y, Shen G, Song S (2018) A nomogram for predicting survival in patients with breast cancer brain metastasis. Oncol Lett. https://doi.org/10.3892/ol.2018.8259

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sonpavde G, Pond GR, Rosenberg JE, Choueiri TK, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF (2018) Nomogram to assess the survival benefit of new salvage agents for metastatic urothelial carcinoma in the era of immunotherapy. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2018.03.016

    Article  PubMed  PubMed Central  Google Scholar 

  18. Song W, Zhu ZG, Wu Q, Lv CG, Wang YG, Chen L, Miao DL (2018) A nomogram to predict overall survival for biliary tract cancer. Cancer Manag Res 10:1535–1541. https://doi.org/10.2147/cmar.s163291

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zhao J, Sun G, Liao B, Zhang X, Armstrong CM, Yin X, Liu J, Chen J, Yang Y, Zhao P, Tang Q, Wang Z, Chen Z, Li X, Wei Q, Li X, Chen N, Gao AC, Shen P, Zeng H (2018) Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer. 122(6):994–1002. https://doi.org/10.1111/bju.14398

    Article  Google Scholar 

  20. Yang YJ, Lin GW, Li GX, Dai B, Ye DW, Wu JL, Xie HY, Zhu Y (2018) External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer. Asian J Androl 20(2):184–188. https://doi.org/10.4103/aja.aja_39_17

    Article  CAS  PubMed  Google Scholar 

  21. Cronin KA, Ries LA, Edwards BK (2014) The surveillance, epidemiology, and end results (SEER) program of the national cancer institute. Cancer 120(Suppl 23):3755–3757. https://doi.org/10.1002/cncr.29049

    Article  PubMed  Google Scholar 

  22. Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474. https://doi.org/10.1245/s10434-010-0985-4

    Article  PubMed  Google Scholar 

  23. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361–387. https://doi.org/10.1002/(sici)1097-0258(19960229)15:4%3c361:aid-sim168%3e3.0.co;2-4

    Article  PubMed  Google Scholar 

  24. Chen S, Lai Y, He Z, Li J, He X, Shen R, Ding Q, Chen H, Peng S, Liu W (2018) Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection. J Transl Med 16(1):116. https://doi.org/10.1186/s12967-018-1496-5

    Article  PubMed  PubMed Central  Google Scholar 

  25. Wolbers M, Koller MT, Witteman JC, Steyerberg EW (2009) Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology 20(4):555–561. https://doi.org/10.1097/EDE.0b013e3181a39056

    Article  PubMed  Google Scholar 

  26. Fang C, Wang W, Feng X, Sun J, Zhang Y, Zeng Y, Wang J, Chen H, Cai M, Lin J, Chen M, Chen Y, Li Y, Li S, Chen J, Zhou Z (2017) Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer 117(10):1544–1550. https://doi.org/10.1038/bjc.2017.315

    Article  PubMed  PubMed Central  Google Scholar 

  27. Roberto M, Botticelli A, Strigari L, Ghidini M, Onesti CE, Ratti M, Benzoni I, Pizzo C, Falcone R, Lomiento D, Donida BM, Totaro L, Mazzuca F, Marchetti P (2018) Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. Med Oncol 35(7):111. https://doi.org/10.1007/s12032-018-1166-8

    Article  PubMed  Google Scholar 

  28. Cao J, Yuan P, Wang L, Wang Y, Ma H, Yuan X, Lv W, Hu J (2016) Clinical nomogram for predicting survival of esophageal cancer patients after esophagectomy. Sci Rep 6:26684. https://doi.org/10.1038/srep26684

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ (2010) Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 28(23):3762–3769. https://doi.org/10.1200/jco.2009.26.8847

    Article  PubMed  Google Scholar 

  30. Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD (2008) Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 26(3):380–385. https://doi.org/10.1200/jco.2007.14.1291

    Article  PubMed  Google Scholar 

  31. Pierorazio PM, Walsh PC, Partin AW, Epstein JI (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111(5):753–760. https://doi.org/10.1111/j.1464-410X.2012.11611.x

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kim TH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM (2017) Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy. Scand J Urol 51(1):27–32. https://doi.org/10.1080/21681805.2016.1266384

    Article  PubMed  Google Scholar 

  33. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21(7):1232–1237. https://doi.org/10.1200/jco.2003.06.100

    Article  PubMed  Google Scholar 

  34. Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, Kavanagh BD (2014) The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol 32(5):707–713. https://doi.org/10.1016/j.urolonc.2014.01.004

    Article  PubMed  Google Scholar 

  35. Shah S, Boucai L (2018) Effect of Age on Response to Therapy and Mortality in Patients With Thyroid Cancer at High Risk of Recurrence. J Clin Endocrinol Metabol 103(2):689–697. https://doi.org/10.1210/jc.2017-02255

    Article  Google Scholar 

  36. Chen CH, Chang TT, Cheng KS, Su WW, Yang SS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN (2006) Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int 26(7):766–773. https://doi.org/10.1111/j.1478-3231.2006.01309.x

    Article  PubMed  Google Scholar 

  37. Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P (2018) Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol 29(2):377–385. https://doi.org/10.1093/annonc/mdx742

    Article  CAS  PubMed  Google Scholar 

  38. Guo X, Zhang C, Guo Q, Xu Y, Feng G, Li L, Han X, Lu F, Ma Y, Wang X, Wang G (2018) The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer. Cancer Manag Res 10:1639–1646. https://doi.org/10.2147/CMAR.S168579

    Article  PubMed  PubMed Central  Google Scholar 

  39. Bai DS, Chen P, Qian JJ, Jin SJ, Jiang GQ (2017) Effect of marital status on the survival of patients with gallbladder cancer treated with surgical resection: a population-based study. Oncotarget 8(16):26404–26413. https://doi.org/10.18632/oncotarget.15476

    Article  PubMed  PubMed Central  Google Scholar 

  40. Zhou H, Zhang Y, Song Y, Tan W, Qiu Z, Li S, Chen Q, Gao S (2017) Marital status is an independent prognostic factor for pancreatic neuroendocrine tumors patients: an analysis of the surveillance, epidemiology, and end results (SEER) database. Clin Res Hepatol Gastroenterol. https://doi.org/10.1016/j.clinre.2017.02.008

    Article  PubMed  Google Scholar 

  41. Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Hu JC, Nguyen PL (2013) Marital status and survival in patients with cancer. J Clin Oncol 31(31):3869–3876. https://doi.org/10.1200/jco.2013.49.6489

    Article  PubMed  PubMed Central  Google Scholar 

  42. Zhou R, Yan S, Li J (2016) Influence of marital status on the survival of patients with gastric cancer. J Gastroenterol Hepatol 31(4):768–775. https://doi.org/10.1111/jgh.13217

    Article  PubMed  Google Scholar 

  43. Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ (2007) Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 177(2):505–509. https://doi.org/10.1016/j.juro.2006.09.039

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Urology and Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, No.141, Tianjin Road, Huangshi, Hubei, 435000, People’s Republic of China

    Wei-dong Jiang & Ping-cheng Yuan

Authors
  1. Wei-dong Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ping-cheng Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

WDJ and PCY collected, analyzed, interpreted the data, and wrote the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ping-cheng Yuan.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, Wd., Yuan, Pc. Development and validation of prognostic nomograms for patients with metastatic prostate cancer. Int Urol Nephrol 51, 1743–1753 (2019). https://doi.org/10.1007/s11255-019-02224-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-019-02224-z

Keywords

Search

Navigation